PET Imaging in Patients With Prostate CancerPhase 1/2NCT07056439
Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients
A Phase 1/2 study testing HRS-1738 Injection in people with PET Imaging in Patients With Prostate Cancer, run by Jiangsu HengRui Medicine Co., Ltd. at 1 site in China.
Trial summary
This study aims to evaluate the safety and pharmacokinetics of HRS-1738 injection in adult patients with prostate cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- PET Imaging in Patients With Prostate Cancer
- What is being tested?
- HRS-1738 Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteChina
- Study dates
- Jul 2025to Aug 2026
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be able to understand and abide by the procedures and requirements of this study and voluntarily sign the informed consent form.
- Male, aged ≥18 years old.
- ECOG (Eastern Oncology Collaboration) Physical Condition score: 0 or 1.
- Prostate adenocarcinoma confirmed by histopathology.
- The distance between enrollment and the most recent surgical treatment should be at least 12 weeks. If the patient has recovered from the surgery before enrollment and meets other enrollment criteria, it can be relaxed to 8 weeks as determined by the investigator.
- The functions of the major organs should meet the requirements.
- For male subjects, they need to agree to take effective contraceptive measures with their partners within one week after the last administration of the investigational drug from the date of signing the informed consent form, and have no plans for fertility and do not donate sperm.
Who cannot join
- Combined with the following diseases:
- . Severe urinary incontinence, hydronephrosis, severe urinary dysfunction, etc. Note: Subjects with bladder outflow tract obstruction or urinary incontinence who can be controlled through the existing best standard treatment (including urinary pads, drainage, etc.) are eligible to participate in the study.
- . Concurrent active infection or unexplained fever >38.5℃ for more than 1 hour during the screening period and before administration.
- . Combined with severe or poorly controlled systemic diseases, including but not limited to poorly controlled diabetes, congestive heart failure, unstable angina pectoris, myocardial infarction that occurred within 6 months before administration, refractory hypertension, acute kidney injury, stroke, and severe liver injury.
- . Combined with active hepatitis B (HBV-DNA testing is required for HBsAg positive patients, and HBV DNA≥2000 IU/mL or 104 copies/mL), active hepatitis C (HCV-Ab positive and higher than the detection limit of the analytical method).
- . Those who are known to have tested positive for acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV).
Show all 13Show fewer
- . Active syphilis infected individuals.
- According to the NCI-CTCAE v5.0 classification, those whose toxicity caused by previous anti-tumor treatment has not yet recovered to grade ≤1 (except for decreased lymphocyte count alone, alopecia, and the indicators mentioned in the inclusion criteria; According to the judgment of the researchers, after consultation with the sponsor, some tolerable chronic grade 2 toxicities may be excluded.
- There are any factors that prevent the smooth progress of PET/CT examination or interfere with the interpretation of imaging results, including but not limited to the following situations: such as inability to lie flat, remain still or tolerate PET/CT scanning; It is known that there are metal implants or joint prostheses, etc.
- It is known that there is an allergy or contraindication to any component of the test drug or its preparation.
- Patients who had a second primary malignant tumor other than prostate cancer before enrollment, excluding malignant tumors with a low risk of metastasis and death that have been cured (5-year survival rate >90%), such as superficial squamous cell carcinoma of the skin, low-grade superficial bladder cancer, etc.
- History of neurological or mental disorders, including epilepsy or dementia.
- Participating in other clinical studies or having less than 4 weeks since the end of the last administration of the previous clinical study at the time of the first administration.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142
Zhi Yang, +86-010-88197842, pekyz@163.com
Peng Du, +86-010-88197842, dupeng9000@126.com
About this study
Official title: A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Preliminary Diagnostic Efficacy of HRS-1738 in PET/CT Imaging of Patients With Prostate Cancer
This study aims to evaluate the safety and pharmacokinetics of HRS-1738 injection in adult patients with prostate cancer.
- Being tested
- HRS-1738 Injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HRS-1738 InjectionDrug
HRS-1738 injection.
| Study group | Role | What they receive |
|---|---|---|
| HRS-1738 Group | Experimental | Not described Receives: Drug: HRS-1738 Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adverse events (AEs)
Measured: About 1 year.
Serious adverse events (SAEs)
Measured: About 1 year.
Secondary outcomes (3)
The maximum blood drug concentration (Cmax)
Measured: About 1 year.
Time to peak (Tmax)
Measured: About 1 year.
Biological half-life (t1/2)
Measured: About 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study startJul 2025 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PET Imaging in Patients With Prostate CancerStudies of the same condition, open and under way.
- More trials run by Jiangsu HengRui Medicine Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07056439
- Sponsor's protocol ID
- HRS-1738-101
- Status last verified
- Jun 2025
- First submitted
- 30 Jun 2025
- Last updated
- 9 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided